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Trends in osteoporosis and mean
bone density among type 2
diabetes patients in the US
from 2005 to 2014
Yingke Xu1,2 & Qing Wu

1,2*

This study aimed to examine how bone health changed among T2DM patients in the past decade.
Continuous National Health and Nutrition Examination Survey (NHANES) data from 2005–2006 to
2013–2014 were analyzed to examine the trends of bone mineral density (BMD) and the prevalence
trends of osteoporosis osteopenia among T2DM patients and non-diabetic people aged 40 years and
older. The age- and BMI-adjusted mean BMD of the femur neck for the four NHANES cycles decreased
linearly in both T2DM patients and non-diabetic people (both Plinear trend ≤ 0.009). Among women
with T2DM, the mean BMD in 2013–2014 was significantly lower than that in 2005–2006, even after
adjusting for multiple covariates. During 2005–2014, the prevalence of osteoporosis among T2DM
patients and non-diabetic people increased but with no significant linear trend (both Plinear trend > 0.05),
while the prevalence of osteopenia in the two populations increased linearly (both Plinear trend < 0.04).
Age- and BMI-adjusted mean BMD decreased in 2013–2014 in patients with T2DM and non-diabetic
people, while the prevalence of osteoporosis and osteopenia increased in both groups.
Osteoporosis and low bone mass (osteopenia) affect approximately 200 million people across the world1, including 54 million people in the United S tates2. People with these conditions are prone to have fractures. Indeed,
around 158 million people were at a high fracture risk in 2010, with that number predicted to double by 2 0143.
These related fractures will ultimately lead to many issues in those afflicted, including movement restriction,
disability, and severe morbidity.
Diabetes is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or
both4,5. The number of people with diabetes worldwide has risen from 108 million in 1980 to 422 million in
20146. Even more notably, type 2 diabetes mellitus (T2DM) accounts for 90–95% of all d
 iabetes7. The prevalence
of diabetes increased rapidly from 4.4 to 10.0% in the US between 1996 and 20158, and more than 30 million
suffer from T
 2DM9.
Osteoporosis and T2DM are affected by aging and often coexist in the e lderly10. T2DM affects bone metabolism and strength by influencing osteoblast and osteoclast11. The imbalance between osteoblast and osteoclast
might cause osteoporosis11. As well, T2DM might affect bone quality and quantity, leading to a change in the
structural properties of bone mass12. T2DM affects bone homeostasis, so related fractures are considered a
result of T2DM12,13. Several studies have already reported an increased fracture risk among T2DM patients14–17.
Therefore, evaluating the bone health of individuals with T2DM is essential in preventing osteoporosis and
related fractures. However, to our knowledge, how the bone health of T2DM patients changed in recent years
remains unclear. As BMD is the most important single predictor for osteoporotic fractures, the dual-energy
X-ray absorptiometry (DXA)-based BMD has been the benchmark technique used in osteoporosis d
 iagnosis18,19.
DXA-based BMD plays a crucial role in osteoporosis/osteopenia management and fracture risk assessment.
Therefore, the present study aimed to test whether people with T2DM have had an elevated or decreased BMD
in the past decades and compare the results to non-diabetic people. We also examined the trends of osteoporosis
and osteopenia prevalence in T2DM patients and non-diabetic people.
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Methods

Data source. Data were obtained from the continuous National Health and Nutrition Examination Survey

(NHANES). The survey uses a complex, multistage probability design to select a nationally representative sample
of non-institutionalized civilians in the US p
 opulation20. NHANES collects data through interviews and physical examination. The interview includes demographic, socioeconomic, dietary, and health-related questions,
while the examination consists of medical, dental, and physiological measurements. From 2005–2006, the survey started measuring femur and spine BMD; however, the BMD was not measured for NHANES in 2011–2012.
Therefore, only four cycles (2005–2006, 2007–2008, 2009–2010, and 2013–2014) were included for this study.
Subjects younger than 40 years old were excluded since participants are more likely to develop T2DM if they are
40 or over21.

Human participants.

NHANES study protocol was approved by the National Center for Health Statistics
Research Ethics Review Board. Written informed consent was obtained for all adult participants. This secondary
analysis was approved by the institutional review board at the University of Nevada, Las Vegas (#1004670). All
research reported in this manuscript was performed in accordance with relevant guidelines/regulations.

Diabetes mellitus.

Subjects who had a positive response to the question, “Have you ever been told by a
doctor that you have diabetes?” were defined as having a diagnosed diabetes. Individuals who reported taking pills to lower blood sugar were classified as having a diagnosed T2DM as well. This classification method
was used22, and other study using NHANES data adopted this method as w
 ell23. Among participants without
diagnosed diabetes, individuals who had a hemoglobin A1c level of 6.5% or higher, or a fasting plasma glucose
level of 126 mg/dL or higher, or a 2-h plasma glucose level of 200 mg/dL or higher5, were all classified as having
“undiagnosed diabetes.” Because we could not distinguish between type 1 and type 2 diabetes based on these lab
results, all of the undiagnosed diabetes in this study was assumed to be T2DM since T2DM comprises the majority (90–95%) of d
 iabetes7. Diagnosed T2DM and undiagnosed T2DM were combined as the T2DM group in this
study. People were classified as non-diabetic if they did not have diagnosed or undiagnosed diabetes.

BMD measurement.

Femur neck BMD and spine BMD were measured using a Hologic QDR-4500A fanbeam densitometer during 2005–2010. Both BMDs were obtained with a Hologic Discovery model A densitometer (Hologic, Inc., Bedford, MA, USA) in 2013–2014. During 2005–2010, Hologic Discovery v12.4 and APEX
v3.0 were used for analyzing the femur and spine scans, respectively. APEX v4.0 was used for the analysis in
the two regions in 2013–2014. In this study, we focused on analyzing the femur neck BMD primarily because
BMD at the femur neck has the highest predictive value for hip fracture, and the hip is the site of highest clinical
relevance24. We used femur neck BMD over spine BMD in this study because of significant differences in BMD
measures between using Discovery v12.4 during 2005–2010 and using APEX v4.0 in 2013–2014, with the exception of the femur neck25. In NHANES, DXA scans were used for the BMD measurement since the system has
a number of advantages, the primary being a consensus that BMD results can be interpreted using the World
Health Organization T-score definition of osteoporosis, thus having a proven ability to predict fracture r isk26.

Definition for osteoporosis and osteopenia. In this study, the diagnosis of osteoporosis or osteopenia
was based on T-score results. T-scores were calculated as ( BMDmeasured − mean BMDreference)/SDreference. Osteoporosis was defined as a T-score of BMD ≤  − 2.5, and osteopenia was defined as − 2.5 < T-score ≤ − 127. Consistent
with the International Society for Clinical Densitometry’s corresponding guidelines, the reference group for
calculating these scores for the femur neck consisted of 20–29 years old non-Hispanic Caucasian women from
NHANES III28. In our study, subjects who lacked valid BMD data were excluded.
Other variables. Age, sex, race/ethnicity, smoking status, physical activities, fracture history, and family
history were ascertained by questionnaire. For the race/ethnicity groups, “Mexican American” and “Other Hispanic” were merged into a single group called “Hispanic,” and the remaining groups were “non-Hispanic White,”
“non-Hispanic Black,” and “non-Hispanic other,” respectively. BMD-related variables, including body mass index
(BMI), previous f racture29,30, smoking s tatus31,32, physical a ctivity33,34, and family history of o
 steoporosis35, were
considered for analysis. BMI was derived from measured weight in kilograms, divided by the square of height
in meters. Individuals who had suffered a broken or fractured hip, wrist, or spine were considered as having a
previous fracture. Smoking status was categorized into smokers and non-smokers. Smokers were respondents
who had smoked at least 100 cigarettes during their lifetime; otherwise, subjects were defined as non-smokers.
Self-reported physical activity was categorized as “inactive” and “active.” Participants who were sedentary or only
performed basic activities, which refers to light-intensity activities like standing and walking slowly, were considered to be inactive; otherwise, the individuals were classified as a ctive36. In the present study, the participants
were defined as having a family history of osteoporosis if their parent(s) ever had the disease.

Statistical analysis. Sampling weights were utilized to account for unequal selection probabilities, nonresponse, and non-coverage37. The age- and BMI-adjusted mean BMD at the femur neck, prevalence of osteoporosis and osteopenia, and corresponding 95% confidence interval in every survey cycle for both T2DM patients
and non-diabetic people were calculated based on weighted data. Standard errors, which were employed to calculate 95% confidence intervals, were estimated using Taylor series linearization. The US 2000 Census was used
as the standard population for age adjustment. Tests for linear trend over the four survey cycles were conducted
using orthogonal contrast. Multiple linear regression was used to examine the BMD trend while holding other
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Survey cycle
2005–2006

2007–2008

2009–2010

2013–2014

With T2DM
(N = 409)

Non-diabetic
(N = 1853)

With T2DM
(N = 720)

Non-diabetic
(N = 2465)

With T2DM
(N = 734)

Non-diabetic
(N = 2619)

With T2DM
(N = 674)

Non-diabetic
(N = 2427)

Age, mean (SD),
years

62.12 ± 0.85

55.51 ± 0.71

61.47 ± 0.51

55.60 ± 0.32

62.47 ± 0.72

55.84 ± 0.39

61.22 ± 0.71

56.42 ± 0.34

BMI, mean (SD),
kg/m2

29.93 ± 0.30

27.75 ± 0.21

31.32 ± 0.29

27.74 ± 0.12

31.23 ± 0.27

27.86 ± 0.14

31.38 ± 0.26

28.27 ± 0.19

Men

227 (53.26)

975(48.53)

394 (51.87)

1209 (46.39)

377 (52.12)

1323 (48.08)

371 (57.04)

1162 (47.81)

Women

182 (46.74)

878 (51.47)

326 (48.13)

1256 (53.61)

357 (47.88)

1296 (51.92)

303 (42.96)

1265 (52.19)

Hispanic

115 (13.33)

323 (7.05)

208 (11.92)

617 (9.21)

260 (15.67)

678 (9.76)

192 (16.44)

496 (10.26)

NH White

166 (66.58)

1108 (80.19)

316 (67.67)

1315 (76.36)

293 (64.45)

1411 (76.17)

234 (61.41)

1132 (73.44)

NH Black

112 (14.60)

356 (8.13)

174 (14.47)

437 (8.75)

134 (12.04)

418 (8.77)

156 (13.26)

462 (9.38)

NH other

16 (5.49)

66 (4.63)

22 (5.94)

96 (5.68)

47 (7.84)

112 (5.29)

92 (8.88)

337 (6.92)

Previous fracture,
N (%)

55 (15.79)

272 (14.97)

89 (13.76)

328 (14.49)

74 (11.22)

306 (12.02)

73(12.80)

260 (12.34)

Smoking, N (%)

226(52.20)

995 (53.61)

380 (52.21)

1245 (48.77)

362 (49.04)

1287 (46.54)

326 (50.96)

1111(45.30)

Physical inactivity,
73 (14.04)
N (%)

244 (9.89)

310 (41.22)

708 (22.40)

308 (38.44)

733 (22.57)

226 (34.61)

612 (23.80)

Family history
of osteoporosis,
N (%)

213 (14.29)

67 (12.71)

334 (16.74)

61 (8.97)

292 (14.47)

74 (13.51)

312 (16.84)

Variable

Gender, N (%)

Race, N (%)

28 (10.17)

Table 1.  Weighted characteristics of subjects aged 40 and older, among T2DM patients and non-diabetic
population in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).

variables constant. The standardized coefficient from linear regression was employed to examine each variable’s
relative importance in the regression model for BMD prediction. The survey cycle was included as a categorical
variable in the multiple linear regression in order to determine if the mean BMD in 2013–2014 differed from
previous survey cycles after adjusting for major confounders. We also conducted separate sensitivity analyses
to examine the mean BMD trends across the four survey cycles in T2DM patients and non-diabetic population
after adjusting for age and weight (instead of BMI) and in diagnosed and undiagnosed T2DM patients after
adjusting for age and BMI. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results

The number of eligible participants in this study was 11,901, and their characteristics by survey cycles are
presented in Table 1. During the four survey cycles, the mean age was around 62 years for T2MD patients and
56 years for the non-diabetic population. From 2005 to 2014 mean BMI increased among T2DM patients (from
29.93 to 31.38 kg/m2), as well as among the non-diabetic population (from 27.75 to 28.27 kg/m2). In each survey
cycle, more than half of T2DM patients were men, while most non-diabetic participants were women. Over the
four survey cycles, the percentage of physical inactivity increased from 14.04 to 34.61% in T2DM patients and
from 9.89 to 23.80% in the non-diabetic population.

Adjusted mean femur neck BMD.

The age- and BMI-adjusted mean BMD of T2DM patients and nondiabetic people in the four survey cycles are shown in Fig. 1a. For T2DM patients, the mean BMD decreased
linearly from 0.813 g/cm2 (95% CI 0.796–0.829 g/cm2) to 0.784 g/cm2 (95% CI 0.771–0.796 g/cm2) during 2005–
2014 (Plinear trend = 0.004). Meanwhile, the mean BMD of non-diabetic also decreased linearly during the four
survey cycles (Plinear trend = 0.0009), from 0.795 to 0.773 g/cm2.
The results of age- and BMI- adjusted mean BMD of T2DM patients stratified by gender are presented in
Fig. 1b. Among patients with T2DM, women had a lower mean BMD than men during the four survey cycles.
In 2005–2014, the mean BMD of women with T2DM linearly decreased ( Plinear trend = 0.007), but no significant
linear trend (Plinear trend = 0.1) was observed among men with T2DM.
The age- and BMI-adjusted mean BMD of the non-diabetic population stratified by gender are presented
in Supplementary Figure 1. Significant linear trends were observed for both genders during 2005–2014 (both
Plinear trend ≤ 0.005). Our sensitivity analysis revealed that the results of age- and weight-adjusted mean BMD (Supplementary Figure 2) were similar to age- and BMI-adjusted mean BMD. In addition, the age- and BMI-adjusted
mean BMD (Supplementary Figure 3) decreased linearly in people with diagnosed T2DM (P linear trend = 0.02), but
not for people with undiagnosed T2DM ( Plinear trend = 0.39) during 2005–2014.

Prevalence of osteoporosis and osteopenia. The age- and BMI-adjusted prevalence of osteoporosis

and osteopenia of T2DM patients and non-diabetic people from 2005 to 2014 are presented in Table 2. The
adjusted prevalence of osteoporosis among T2DM patients increased from 3.13% (95% CI 1.39–4.87%) to
6.10% (95% CI 4.47–7.75%) during 2005–2014, and the linear trend was close to being statistically significant
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Figure 1.  Age and body mass index-adjusted mean bone mineral density in 4 NHANES (2005–2006, 2007–
2008, 2009–2010, and 2013–2014).
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Survey cycle
Prevalence

2005–2006

2007–2008

2009–2010

2013–2014

P value for linear trend

Osteoporosis
T2DM

3.13 (1.39–4.87)

4.50 (1.55–7.44)

3.10 (1.75–4.44)

6.10 (4.47–7.75)

0.054

Non diabetic

4.03 (3.26–4.79)

3.03 (2.30–3.74)

3.81 (3.18–4.46)

4.38 (3.39–5.37)

0.35

Osteopenia
T2DM

27.83 (21.62–34.03)

31.14 (26.75–35.54)

32.56 (27.15–37.97)

35.49 (30.06–40.92)

0.04

Non diabetic

32.23 (29.81–34.64)

30.27 (28.14–32.41)

32.82 (30.81–34.84)

38.20 (35.51–40.90)

0.0005

Table 2.  Age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients and nondiabetic population in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).

Survey cycle
Prevalence

2005–2006

2007–2008

2009–2010

2013–2014

P value for linear trend

Osteoporosis
Men

0.02 (0–0.30)

2.29 (0–4.87)

1.31 (0–2.63)

Women

3.95 (0–7.98)

4.95 (1.67–8.23)

3.19 (0.81–5.57)

1.21 (0.42–2.00)

0.14

10.13 (6.06–14.21)

0.08

Osteopenia
Men

21.34 (14.34–28.34)

22.44 (18.05–26.82)

20.98 (14.68–27.28)

27.14 (19.01–35.26)

0.35

Women

25.22 (18.82–31.62)

31.13 (25.08–37.17)

35.34 (27.52–43.15)

35.42 (26.82–44.02)

0.04

Table 3.  Age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients stratified
by gender in 4 NHANES (2005–2006, 2007–2008, 2009–2010, and 2013–2014).

(Plinear trend = 0.054). For non-diabetic individuals, the adjusted prevalence of osteoporosis was stable during this
period (Plinear trend = 0.35). The adjusted osteopenia prevalence of T2DM patients and non-diabetic people had a
significant increase in the linear trend (both Plinear trend ≤ 0.04).
The age- and BMI-adjusted prevalence of osteoporosis and osteopenia among T2DM patients by gender are
presented in Table 3. The linear trend of the osteoporosis prevalence among women approached the borderline
of significance (Plinear trend = 0.08) but was non-significant for men (Plinear trend = 0.14). The osteoporosis prevalence
among women with T2DM increased from 3.95% (95% CI 0–7.98%) to 10.13% (95% CI 6.06–14.21%) during
the four survey cycles. For the prevalence of osteopenia among T2DM patients, a significant increase in linearly
trend was observed in women ( Plinear trend = 0.04), but not in men ( Plinear trend = 0.35). The prevalence of osteoporosis and osteopenia in non-diabetic people by gender is presented in Supplementary Table 1. The prevalence of
osteoporosis in non-diabetic men and women was stable during the four survey cycles (both P
 linear trend > 0.29).
However, significant linear trends in osteopenia prevalence were observed in non-diabetic men and women
during the four survey cycles (both P
 linear trend  ≤  0.004).

Multiple linear regression. For women with T2DM, older age and previous fractures were significantly
associated with decreased BMD, based on the multiple linear regression (both p ≤ 0.03; Supplementary Table 2).
For men with T2DM, older age, family history of osteoporosis, physical inactivity, and smoking were associated
with significant BMD reduction (all p < 0.007; Supplementary Table 3). The standardized coefficient revealed
that age played a more critical role than other risk factors in lowering BMD for T2DM patients of both sexes. The
selected covariates explained around 35% variance of BMD at the femur neck in women and about 27% in men.
The mean BMD of women with T2DM in 2013–2014 was significantly lower than in 2005–2006 (p = 0.0007;
Supplementary Table 2), even after adjusting for various confounders. The results of non-diabetic individuals,
both women and men, are respectively presented in Supplementary Table 4 and Table 5. For non-diabetic people,
a family history of osteoporosis, age, and physical inactivity had a significant negative impact on BMD in both
men and women.

Discussion

In this study, decreasing BMD trends at the femur neck were observed among T2DM patients and non-diabetic
people during 2005–2014. In addition, the prevalence of osteoporosis and osteopenia among subjects with
T2DM increased correspondingly in the four survey cycles. Specifically, a significant increasing linear trend
in the prevalence of osteoporosis and osteopenia was observed among women with T2DM. These consistent
results demonstrate that an unfavorable trend of change in bone health in T2DM patients may be occurring in
the United States.
Compared to our prior study regarding the US BMD trend in 2005–201438, the present research further examined the BMD trend, osteoporosis, and osteopenia in the US’s T2DM population. There is a paucity of research
investigating the BMD trend and the pattern of osteoporosis and osteopenia in T2DM patients, specifically a lack
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of data comparing the trend between individuals with T2DM and those without diabetes. In this study, T2DM
patients had a higher BMD than non-diabetic people, consistent with Dr. Oei et al.’s r esearch16,39. Among T2DM
patients, men had a higher BMD mean than women. The possible reason for this is that men have a larger bone
mass than w
 omen40. Notably, the mean BMD in 2013–2014 among women with T2DM was significantly lower
than the mean BMD in 2005–2006. Such a difference remained when adjusted for multiple related factors, implying proper intervention might be needed. Although such a linear trend of BMD was not observed among men
in the current study, attention should be paid to men since a previous study showed that men with diabetes had
a higher risk of fracture41. Our findings of non-diabetic people were consistent with a recent study conducted
by Dr. Chi Chen et al. that found a declining BMD trend among adults with normal glucose regulation42. The
decreasing mean BMD trend of this study demonstrates that the bone health of T2DM patients and non-diabetic
people might have deteriorated significantly in recent years. In Dr. Black and colleagues’ s tudy43, people with the
lowest quartile of BMD almost had fivefold increased hip fracture risk during 25 years follow-up when compared
with those with the highest quartile of BMD. Therefore, as shown in the current study, primary prevention and
treatment should be conducted among the non-diabetic population with the lowest quartile BMD.
The multiple linear regression results indicated that sex, age, race, previous fracture, BMI, smoking, and
physical activity are significant for T2DM patients6,8,27,29–35,44–48. Thus these related risk factors might partially
contribute to the declining trend in mean BMD. The percentage of physical inactivity increased from 14.04 to
34.61% among T2DM and from 9.89 to 23.80% among non-diabetics. Given the association between physical
inactivity and lower BMD34, the increased physically inactive lifestyle might also explain the decreasing BMD
trends occurring during the four survey cycles. However, the decreased BMD in 2013–2014 among women with
T2DM remained significant after controlling for major confounding effects in the multiple regression analysis.
Thus other factors such as antidiabetic medication of T2DM patients may play a role in the observed t rend49,50.
For example, Dr. Monami and colleagues found an increased risk of fracture among T2DM patients who used
insulin51. Patients with insulin usually have complications such as microvascular disease, which might impair
the bone quality and individual balance52, thus increasing fracture risk. Additionally, Schwartz et al. reported an
increased bone loss in diabetic women who had taken thiazolidinediones medication (TZD), including rosiglitazone, pioglitazone, and troglitazone49. Several studies investigated the effect of TZD on bone metabolism and
found it is associated with increased adipogenesis and impaired osteoblastogenesis, which might lead to impaired
bone formation and ultimately to f ractures53. Other studies found that two medications, exenatide (a glucagonlike peptide 1 receptor agonist) and dapagliflozin (a sodium glucose cotransporter-2 inhibitor) increased the risk
of bone fractures54,55, while dipeptidyl peptidase-4 inhibitors were associated with decreased fracture risk26,54,56.
Further research is warranted to explain the overall declining BMD trend in T2DM patients.
The underlying pathogenic mechanism of bone fragility in T2DM is complex and not fully u
 nderstood12. Not
only decreased bone mass but also bone microstructure might contribute to bone fracture. Typically, increased
cortical porosity and reduced cortical density lead to bone structure change52. Prior studies found that T2DM
patients had greater cortical porosity57,58, but lower cortical bone density59. Therefore, bone resistance to mechanical stress among T2DM patients will be increased, which will result in an increased risk of fracture.
Several limitations should be acknowledged in interpreting the finding of this study. First, many of the
NHANES participants were excluded from BMD measurement due to hip fractures, pregnancy, or other reasons.
However, nonresponse in the examination data was accounted for by sampling weights in NHANES. Second,
information about T2DM treatment, which might impact bone health, is limited in NHANES. For example, TZD
is widely prescribed for the treatment of T2DM, and accumulating evidence indicates that TZD could cause bone
loss and increase fracture risk in humans, specifically in women49. However, too few participants reported this
information, so we cannot analyze it to yield valid results. Third, the evaluation of the trend in hemoglobin A1c
among T2DM patients would be informative since several studies reported the association between poor glycemic
control and increased risk of f ractures60–63. However, the missing value of hemoglobin A1c from NHANES is
too much (around 80%) to get an accurate evaluation. Finally, the study design of NHANES is cross-sectional,
which restricts the assessment of causal relationships.
Osteoporosis and low BMD lead to fractures, which cause severe consequences for both individual patients
and health care systems24. Osteoporosis-related fractures often lead to decreased quality of life, disability, and
even death for patients and are also associated with $20 billion in expenses in the US64. Due to T2DM patients
having normal or higher BMD, BMD-based T-score might underestimate the fracture risk of T2DM patients,
and evaluation of bone health and osteoporosis diagnosis among them might be challenging52. Derived from
continuous NHANES data, our findings regarding osteoporosis trends and mean BMD among T2DM patients
can be used to inform public health policy and thus contribute to needed reform. Policy intervention may help
to reduce risk factors associated with the downward trend of bone health inT2DM patients.

Conclusion

In summary, a decreasing age- and BMI-adjusted mean BMD trend has been observed in T2DM patients and
the non-diabetic population in recent years. The unfavorable trend indicates a future downward shift in the bone
health of T2DM patients, so bone health should be monitored in diabetic patients. Therefore, additional studies are warranted to understand the decreasing BMD trend among T2DM patients more thoroughly to prevent
fractures and their subsequent deleterious consequences on individuals with diabetes.
Received: 3 June 2020; Accepted: 14 January 2021
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